Low bone mineral density with tenofovir: Does statistically significant mean clinically significant?

Clinical Infectious Diseases

Volumn 51, Issue 8, 2010, Pages 973-975

  Carr, Andrew ^a   Hoy, Jennifer ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR;

ANTIVIRAL THERAPY; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LUMBAR SPINE; NOTE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; BONE DENSITY; BONE DISEASES; FEMALE; FRACTURES, BONE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PHOSPHONIC ACIDS;

EID: 77957829316     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656418     Document Type: Note

References (15)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006; 20:2165-2174.
2. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
3. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-Infected men irrespective of treatment. J Bone Miner Res 2004; 19:402-409. (Pubitemid 38787395)
4. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
5. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
6. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [abstract 106LB]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 16-19 February 2010.
7. Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51(8):963-972 (in this issue).
8. Martin A, Bloch M, Amin J, et al. Simplification with tenofovir-emtricitabine causes less, serious non-AIDS events than with abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601.
9. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of us adults. Osteoporosis Internat 1998; 8:468-489. (Pubitemid 28486716)
10. Post FA, Moyle G, Stellbrink HJ, et al. Randomized comparison of renal effect, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from teh ASSERT study. JAIDS 2010; 5:49-57.
11. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010 [Epub ahead of print].
12. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis 2008. http://www.nof.org/professionals/NOF-Clinicians- Guide.pdf. Accessed 1 July 2010.
13. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV Infection: a cross-sectional study. J Infect Dis 2009; 200:1746-1754.
14. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis Internat 2008; 19:385-397. http://www.shef.ac.uk/FRAX/. Accessed 26 August 2010.
15. Carr A, Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009; 23:343-353.